Venture Kick stage 3 funding for deepCDR Biologics

The 2019-founded ETH spinoff deepCDR Biologics, which originated from the Laboratory of Systems and Synthetic Immunology led by Professor Sai Reddy, develops a novel antibody discovery workflow, combining drug screening in mammalian cells with deep learning to generate thousands of optimised lead antibody candidates. The method will help advance the treatment of cancer, immunological disorders, and infectious diseases such as COVID-19.